Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India.
Pediatr Allergy Immunol. 2021 Apr;32(3):479-488. doi: 10.1111/pai.13415. Epub 2020 Dec 4.
Vitamin D supplementations for asthma control had shown inconsistent results. We aimed to study efficacy and safety of vitamin D supplementation in asthmatic children who were vitamin D deficient.
This double-blind, randomized controlled trial enrolled asthmatic children of 4-12 years of age who had 25-hydroxyvitamin D [25(OH)D] levels <20 ng/mL. The participants were randomized to receive either vitamin D orally 1000 IU/d for 9 months or similar-looking placebo. The primary outcomes were the proportion of children having the Childhood Asthma Control Test (CACT) score of ≥20 at the end of the treatment and adverse effects.
The trial included 250 children (125 in each group) with a mean age of 8.1 ± 2.3 years and 180 boys. The baseline parameters were similar between the groups, including CACT score (21.7 ± 4.2 vs 21.9 ± 3.6, vitamin D vs placebo). At the end of the study, the proportion of asthmatic children who had CACT score ≥ 20 was similar between vitamin D and placebo group (93.6% vs 92.0%, P = .625). The number of exacerbations of asthma and side effect profile was also identical between the groups. 25(OH)D levels increased significantly in the vitamin D group (18.06 ± 7.11 vs 12.03 ± 5.98 ng/mL, P < .001). The results did not change when we did subgroup analysis for children with baseline CACT score < 20 and 25(OH)D levels at the end of the study ≥20 ng/mL.
Vitamin D supplementation in asthmatic children with vitamin D deficiency did not improve control of asthma.
维生素 D 补充剂在哮喘控制方面的效果并不一致。我们旨在研究维生素 D 缺乏的哮喘儿童补充维生素 D 的疗效和安全性。
这是一项双盲、随机对照试验，纳入了年龄在 4-12 岁、25-羟维生素 D [25(OH)D]水平<20ng/ml 的哮喘儿童。参与者被随机分为口服维生素 D 1000IU/d，持续 9 个月，或服用外观相似的安慰剂。主要结局是治疗结束时儿童的儿童哮喘控制测试（CACT）评分≥20 的比例和不良反应。
该试验纳入了 250 名儿童（每组 125 名），平均年龄为 8.1±2.3 岁，180 名男孩。两组的基线参数相似，包括 CACT 评分（21.7±4.2 与 21.9±3.6，维生素 D 与安慰剂）。研究结束时，维生素 D 组和安慰剂组 CACT 评分≥20 的哮喘儿童比例相似（93.6%与 92.0%，P=0.625）。哮喘发作次数和不良反应谱也无差异。维生素 D 组 25(OH)D 水平显著升高（18.06±7.11 与 12.03±5.98ng/ml，P<0.001）。当我们对基线 CACT 评分<20 和研究结束时 25(OH)D 水平≥20ng/ml 的儿童进行亚组分析时，结果并未改变。
维生素 D 缺乏的哮喘儿童补充维生素 D 并不能改善哮喘控制。
